Security Asset Management decreased its stake in Celgene Corporation (NASDAQ:CELG) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,243 shares of the biopharmaceutical company’s stock after selling 361 shares during the period. Security Asset Management’s holdings in Celgene Corporation were worth $777,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Edgewood Management LLC raised its position in Celgene Corporation by 0.6% in the fourth quarter. Edgewood Management LLC now owns 9,588,534 shares of the biopharmaceutical company’s stock valued at $1,109,873,000 after buying an additional 53,467 shares during the last quarter. United Bank bought a new stake in shares of Celgene Corporation during the fourth quarter worth about $408,000. Glenview Trust Co bought a new stake in shares of Celgene Corporation during the fourth quarter worth about $7,739,000. Millie Capital Management LLC raised its stake in shares of Celgene Corporation by 109.1% in the fourth quarter. Millie Capital Management LLC now owns 30,534 shares of the biopharmaceutical company’s stock worth $3,534,000 after buying an additional 15,931 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in shares of Celgene Corporation during the fourth quarter worth about $286,000. 78.39% of the stock is owned by institutional investors.
Shares of Celgene Corporation (CELG) traded down 0.04% on Friday, hitting $134.10. The stock had a trading volume of 3,794,219 shares. The firm has a 50 day moving average of $131.06 and a 200 day moving average of $122.99. The stock has a market cap of $104.91 billion, a P/E ratio of 41.65 and a beta of 1.89. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 73.19% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the business earned $1.44 earnings per share. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on CELG shares. Cann reissued a “buy” rating and set a $148.00 target price on shares of Celgene Corporation in a research note on Tuesday, April 4th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $148.00 price objective on shares of Celgene Corporation in a research note on Wednesday, April 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $154.00 price objective on shares of Celgene Corporation in a research note on Tuesday, April 11th. Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a research note on Wednesday, April 19th. Finally, Barclays PLC reaffirmed an “equal weight” rating and issued a $125.00 price objective (up from $120.00) on shares of Celgene Corporation in a research note on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have assigned a buy rating to the company’s stock. Celgene Corporation presently has an average rating of “Buy” and an average price target of $143.61.
In other Celgene Corporation news, Director James J. Loughlin sold 18,500 shares of the business’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $133.57, for a total transaction of $2,471,045.00. Following the sale, the director now directly owns 32,877 shares in the company, valued at $4,391,380.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the sale, the insider now owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 237,005 shares of company stock worth $31,515,142. 0.95% of the stock is owned by company insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.